Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (18955)	4/12/1998 8:11:00 PM
From: Hippieslayer	Read Replies (3) \| Respond to of 32384

If Panretin shows to work well against Acne and/or wrinkles, this stock will go gang busters.

To: WTDEC who wrote (18955)	4/12/1998 9:11:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Walter, Panretin activates all six known receptors (3 RARs and 3 RXRs) while Targretin activates the three RXRs and LGD1550 activates the three RARs, so theoretically, Panretin could have any applications for any of the above as well as the commercial products, Retin-A, Renova, or Accutane, which act through RARs. At the present time topical Targretin is in trials for CTCL and Actinic Keratosis and of course Retin-A, Renova, and Accutane are topical treatments for acne, psoriasis, and wrinkles. Interstingly, for psoriasis, LGND chose to initiate clinical trials using the oral formulation (for both Panretin and Targretin). For off label use of the topical formulation of Panretin however, I suspect that significant use would require some initial clinical data, and to my knowledge, topical Panretin is only being used to treat KS.

To: WTDEC who wrote (18955)	4/12/1998 10:14:00 PM
From: Flagrante Delictu	Respond to of 32384

WTDEC, LGND conducted Phase 2 trials in several cancer indications with Panretin Oral & chose not to go on to P3 trials, even though there was a not insubstantial postponing of the progression of the tumors, because it didn't shrink those tumors. At the announcement of the discontinuation, LGND did point out that a halting of tumor progression was a good thing in & of itself, but they preferred to use their limited resources in even more promising indications. At some future time, when the capsules have been approved for KS or whatever, they will have those P2 results to show.